Author Correction: First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort IKF-AIO-MOONLIGHT trial

Correction to: Nature Communications https://doi.org/10.1038/s41467-026-69622-7, published online 27 February 2026

(Zugehörige Publikation)

First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort trial

Lorenzen, Sylvie; Goetze, Thorsten Oliver; Thuss-Patience, Peter C; Riera-Knorrenschild, Jorge; Goekkurt, Eray; Dechow, Tobias Nicolaas; Ettrich, Thomas Jens; Hofheinz, Ralf Dieter; Luley, Kim Barbara; Pink, Daniel; Lindig, Udo; Folprecht, Gunnar; Schuch, Gunter; Bitzer, Michael; Heinemann, Volker; Angermeier, Stefan; Bolling, Claus; Loose, Maria; Junge, Sabine; Pauligk, Claudia; Al-Batran, Salah-Eddin

Erschienen in:: Nature communications
Verlag:: Springer Science and Business Media LLC
Nature Publishing Group UK
Verlagsort:: [London]
[London]
Jahrgang:: 17
Heft:: 1
ISSN:: 2041-1723
Datum der Veröffentlichung:: 2026
URN:: urn:nbn:de:gbv:8:3-2026-00695-9
DOI:: 10.1038/s41467-026-72255-5
Sonstiger Identifikator (pubmed):: 41997916
Sprache:: Englisch
Ressourcentyp:: Text
Verlag:: Springer Science and Business Media LLC
Schlagwörter:: Humans; Adenocarcinoma; Esophageal Neoplasms; Stomach Neoplasms; Organoplatinum Compounds; Fluorouracil; Leucovorin; Antineoplastic Combined Chemotherapy Protocols; Treatment Outcome; Cohort Studies; Adult; Aged; Middle Aged; Female; Male; Ipilimumab; Oxaliplatin; Nivolumab; Progression-Free Survival; Immune Checkpoint Inhibitors
Klassifikation:: Published Version
DDC-Sachgruppe der DNB:: 610 Medizin, Gesundheit
Einrichtung:: Fakultäten, Medizinische Fakultät
Einrichtung:: Angegliederte Einrichtungen, Universitätsklinikum Schleswig-Holstein (UKSH)